8. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is one of the most exciting biotech stocks in the RNA medicine space because it has moved beyond being a platform story and is now proving that RNA interference can generate blockbuster-level commercial results. Based on latest market data, Alnylam traded at $286.98, with a market capitalization of about $39.67 billion and a P/E ratio near 72.11. That valuation is not cheap, but high-quality biotech growth rarely is. Investors are paying for leadership in RNAi therapeutics, accelerating TTR revenue, and a deep pipeline that could support growth well beyond 2026.
Alnylam’s Q1 2026 report was a major milestone. The company achieved global net product revenue of $1.036 billion, up 121% compared with Q1 2025. Total TTR revenue reached $910 million, up 153% year over year, driven mainly by AMVUTTRA. The company reiterated 2026 combined net product revenue guidance of $4.9 billion to $5.3 billion, including total TTR net product revenue of $4.4 billion to $4.7 billion. The company also reported non-GAAP diluted EPS of $1.99, up sharply from $0.29 in the prior-year period.
CEO Yvonne Greenstreet said Q1 2026 marked “over $1 billion in quarterly product revenues for the first time” in Alnylam’s history, while also pointing to pipeline progress across three Phase 3 trials and a new obesity and weight-management program. That is the kind of statement investors pay attention to because it signals both commercial maturity and continued innovation. The risk is valuation: ALNY is priced as a high-growth biotech leader, so any slowdown in AMVUTTRA, competitive pressure in ATTR-CM, or pipeline disappointment could create volatility. But for investors looking for a top biotech stock with a proven platform, fast-growing product revenue, and long-term RNAi leadership, Alnylam is one of the most compelling names in the market
Click next to see the following stock...
